Platelet rich-plasma - PRP - intraosseous and intra-articular admnistration
Platelet rich-plasma - PRP - intraosseous and intra-articular admnistration: Group 1 will receive two intraosseous injections of PRP and a subsequent/synchronous intra-articular injection of PRP on the same day.
Group 2 will only receive two intra-articular injections of PRP, separated by one week.
Study summary
This is a prospective cohort clinical study. Due to logistic constraints at the sites of implementation, a randomized allocation will not be feasible (private clinic). Patients will be selected with the aim of matching for important confounders (sex and age) the grade of knee OA will be restricted to advance stages.
Eligibility
Sex
ALL
Min age
45 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Adult individuals with unilateral or bilateral symptomatic knee OA diagnosis according to the American College of Rheumatology
* with symptoms for more than 3 months
* confirmed with radiologic diagnosis (Kellgren-Lawrence grades III or IV).
* Patients must be able to walk with a painful knee.
Exclusion Criteria:
* previous history of knee surgery
* systemic autoimmune or rheumatic disease
* platelet diseases
* use of NSAIDs 3 days prior the injections
* previous history (last 3 months) of systematic use of corticosteroids
* or other intra-articular injections in the knee in the past 6 months
Primary outcome measure(s)
PROM - Knee related Qol — baseline, and at follow-up of 3 months, 6 months and 12 months Knee injury and Osteoarthritis Outcome Score (KOOS) - absolute value from the score (units). Min-Max (0-100) higher scores indicate better outcomes and a higher quality of life related to the knee
PROM - PAIN — baseline, and at follow-up of 3 months, 6 months and 12 months Visual analogic Score - PAIN (VAS) -absolute value from the score (units). Min-Max (0-10) higher scores indicate worse outcomes
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
